Cargando…
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
Radiotherapy (RT) is a common treatment for localised prostate cancer, but can cause important side effects. The therapeutic efficacy of RT can be enhanced by pharmacological compounds that target specific pathways involved in cell survival. This would elicit a similar therapeutic response using low...
Autores principales: | Diaz, R, Nguewa, P A, Diaz-Gonzalez, J A, Hamel, E, Gonzalez-Moreno, O, Catena, R, Serrano, D, Redrado, M, Sherris, D, Calvo, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661786/ https://www.ncbi.nlm.nih.gov/pubmed/19240717 http://dx.doi.org/10.1038/sj.bjc.6604938 |
Ejemplares similares
-
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
por: Sato, K, et al.
Publicado: (2006) -
Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy
por: Koukourakis, M I, et al.
Publicado: (2014) -
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017) -
Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2)
por: Olea-Herrero, N, et al.
Publicado: (2009) -
Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer
por: Sacca, P, et al.
Publicado: (2007)